FDA approves standalone use of J&J's ketamine-derived depression treatment Reuters
FDA nod makes J&J's Spravato first solo treatment for resistant depression FirstWord Pharma
Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent Depression AJMC.com Managed Markets Network
J&J’s Spravato first approval as monotherapy for treatment-resistant depression The Pharma Letter
FDA Approves Esketamine as First Monotherapy for Treatment-Resistant Depression MD Magazine
FDA approves SPRAVATO as first monotherapy for MDD Investing.com
FDA approves Johnson & Johnson’s nasal spray for depression as standal
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment CNBC
FDA approves SPRAVATO as first monotherapy for MDD By Investing.com Investing.com UK
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression PR Newswire
